NasdaqGS - Nasdaq Real Time Price • USD
Arrowhead Pharmaceuticals, Inc. (ARWR)
As of 11:38 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 13 | 12 |
| Avg. Estimate | -0.16 | -0.63 | -2.67 | -2.66 |
| Low Estimate | -0.95 | -0.95 | -4.07 | -3.98 |
| High Estimate | 3.27 | -0.24 | -1.26 | -1.46 |
| Year Ago EPS | 0.45 | -0.96 | -1.92 | -2.67 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 11 | 13 | 13 |
| Avg. Estimate | 63.87M | 29.52M | 139.03M | 156.01M |
| Low Estimate | -- | -- | 53.55M | -- |
| High Estimate | 250M | 75.5M | 302M | 286.1M |
| Year Ago Sales | -- | -- | 240.74M | 139.03M |
| Sales Growth (year/est) | -- | -- | -42.20% | 12.20% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.64 | -0.65 | -0.6 | -0.82 |
| EPS Actual | 0.45 | -0.96 | -1.02 | -1.24 |
| Difference | 1.09 | -0.31 | -0.42 | -0.42 |
| Surprise % | 170.30% | -47.70% | -70.00% | -51.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.16 | -0.63 | -2.67 | -2.66 |
| 7 Days Ago | -0.16 | -0.63 | -2.67 | -2.63 |
| 30 Days Ago | -0.16 | -0.63 | -2.67 | -2.63 |
| 60 Days Ago | -0.16 | -0.63 | -2.67 | -2.63 |
| 90 Days Ago | -0.39 | -0.83 | -3.25 | -3.24 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | 1 |
Growth Estimates
| CURRENCY IN USD | ARWR | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -135.60% | -- | -- | 0.30% |
| Next Qtr. | 34.40% | -- | -- | 9.80% |
| Current Year | -39.10% | -- | -- | 4.50% |
| Next Year | 0.40% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 7.33% | -- | -- | 11.06% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/8/2024 |
| Maintains | Citigroup: Neutral to Neutral | 2/7/2024 |
| Reiterates | RBC Capital: Outperform to Outperform | 2/7/2024 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 2/7/2024 |
| Reiterates | RBC Capital: Outperform to Outperform | 1/16/2024 |
| Maintains | B of A Securities: Buy to Buy | 1/2/2024 |
Related Tickers
ALNY Alnylam Pharmaceuticals, Inc.
144.14
-1.32%
PRQR ProQR Therapeutics N.V.
2.0150
-0.25%
AXSM Axsome Therapeutics, Inc.
72.01
-1.46%
RARE Ultragenyx Pharmaceutical Inc.
44.18
-2.06%
BBIO BridgeBio Pharma, Inc.
25.04
-1.65%
MDGL Madrigal Pharmaceuticals, Inc.
214.50
-1.78%
TGTX TG Therapeutics, Inc.
14.21
-0.28%
CYTK Cytokinetics, Incorporated
66.33
+1.15%
SAGE Sage Therapeutics, Inc.
14.03
+8.34%
BPMC Blueprint Medicines Corporation
92.86
+0.61%